These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 28579725)

  • 1. Cost-Savings From an Antipsychotic Tablet-Splitting Program.
    Carey H; Fondriest M
    P T; 2017 Jun; 42(6):384-393. PubMed ID: 28579725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data.
    Rajagopalan K; Hassan M; O'Day K; Meyer K; Grossman F
    J Med Econ; 2013 Jul; 16(7):951-61. PubMed ID: 23701260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The practice of splitting tablets: cost and therapeutic aspects.
    Bachynsky J; Wiens C; Melnychuk K
    Pharmacoeconomics; 2002; 20(5):339-46. PubMed ID: 11994043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia.
    Rajagopalan K; Trueman D; Crowe L; Squirrell D; Loebel A
    Pharmacoeconomics; 2016 Jul; 34(7):709-21. PubMed ID: 27067724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequency and predictors of tablet splitting in statin prescriptions: a population-based analysis.
    Dormuth CR; Schneeweiss S; Brookhart AM; Carney G; Bassett K; Adams S; Wright JM
    Open Med; 2008; 2(3):e74-82. PubMed ID: 21602952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of splitting risperidone tablets on medication adherence and on clinical outcomes for patients with schizophrenia.
    Weissman EM; Dellenbaugh C
    Psychiatr Serv; 2007 Feb; 58(2):201-6. PubMed ID: 17287376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world adherence assessment of lurasidone and other oral atypical antipsychotics among patients with schizophrenia: an administrative claims analysis.
    Rajagopalan K; Wade S; Meyer N; Loebel A
    Curr Med Res Opin; 2017 May; 33(5):813-820. PubMed ID: 28098496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Annual cost of relapses and relapse-related hospitalizations in adults with schizophrenia: results from a 12-month, double-blind, comparative study of lurasidone vs quetiapine extended-release.
    Rajagopalan K; O'Day K; Meyer K; Pikalov A; Loebel A
    J Med Econ; 2013 Aug; 16(8):987-96. PubMed ID: 23742620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hospitalization risk in bipolar disorder patients treated with lurasidone versus other atypical antipsychotics.
    Ng-Mak D; Halpern R; Rajagopalan K; Loebel A
    Curr Med Res Opin; 2019 Feb; 35(2):211-219. PubMed ID: 29625538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between tablet splitting and compliance, drug acquisition cost, and patient acceptance.
    Fawell NG; Cookson TL; Scranton SS
    Am J Health Syst Pharm; 1999 Dec; 56(24):2542-5. PubMed ID: 10613374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of a tablet-splitting program in patients taking HMG-CoA reductase inhibitors: analysis of clinical effects, patient satisfaction, compliance, and cost avoidance.
    Gee M; Hasson NK; Hahn T; Ryono R
    J Manag Care Pharm; 2002; 8(6):453-8. PubMed ID: 14613379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Certain Pharmaceutical Quality Attributes of Lisinopril Split Tablets.
    Fahelelbom KM; Al-Tabakha MM; Eissa NA; Javadi J
    Sci Pharm; 2016 Oct; 84(4):646-653. PubMed ID: 27727195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tablet splitting: is it worthwhile? Analysis of drug content and weight uniformity for half tablets of 16 commonly used medications in the outpatient setting.
    Helmy SA
    J Manag Care Spec Pharm; 2015 Jan; 21(1):76-86. PubMed ID: 25562775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Actual Versus Expected Doses of Half Tablets Containing Prescribed Psychoactive Substances: A Systematic Review.
    Eserian JK; Lombardo M; Chagas JR; Galduróz JCF
    Prim Care Companion CNS Disord; 2018 Feb; 20(1):. PubMed ID: 29469240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lurasidone Induced Thrombocytopenia: Is it a Signal of Drug Induced Myelosuppression?
    Rafi M; Goyal C; Reddy P; Reddy S
    Indian J Psychol Med; 2018; 40(2):191-192. PubMed ID: 29962579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose Uniformity of Scored and Unscored Tablets: Application of the FDA Tablet Scoring Guidance for Industry.
    Ciavarella AB; Khan MA; Gupta A; Faustino PJ
    PDA J Pharm Sci Technol; 2016 11/12; 70(6):523-532. PubMed ID: 27974592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tablet splitting and weight uniformity of half-tablets of 4 medications in pharmacy practice.
    Tahaineh LM; Gharaibeh SF
    J Pharm Pract; 2012 Aug; 25(4):471-6. PubMed ID: 22544621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medication Adherence, Health Care Utilization, and Costs in Patients With Major Depressive Disorder Initiating Adjunctive Atypical Antipsychotic Treatment.
    Broder MS; Greene M; Yan T; Chang E; Hartry A; Yermilov I
    Clin Ther; 2019 Feb; 41(2):221-232. PubMed ID: 30616973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lurasidone compared to other atypical antipsychotic monotherapies for bipolar depression: A systematic review and network meta-analysis.
    Ostacher M; Ng-Mak D; Patel P; Ntais D; Schlueter M; Loebel A
    World J Biol Psychiatry; 2018 Dec; 19(8):586-601. PubMed ID: 28264635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health Care Cost in Patients With Schizophrenia Treated With Brexpiprazole Versus Other Oral Atypical Antipsychotic Therapy.
    Yan T; Greene M; Chang E; Houle CR; Waters HC; Tarbox MH; Broder MS
    Clin Ther; 2020 Jan; 42(1):77-93. PubMed ID: 31928831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.